Innovating Works

IMAXIO

Desconocido
OptiMalVax: Optimizing a deployable high efficacy malaria vaccine IMAXIO SA participó en un H2020: H2020-SC1-2016-2017 A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vacc...
2016-12-09 - 2022-12-31 | Financiado
MultiViVax: Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria IMAXIO SA participó en un H2020: H2020-SC1-2016-2017 Plasmodium vivax is the most widespread malaria and constitutes a significant proportion of human malaria cases. P. vivax accounts for 100-4...
2016-12-09 - 2022-12-31 | Financiado
BELLEROPHON: comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus... IMAXIO SA participó en un FP7: Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, woun...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.